Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)

NCT05160766 is registered in ClinicalTrials.gov with Oliver Cornely, MD as lead sponsor.

NCT NCT05160766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)
Lead sponsor
Oliver Cornely, MD
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2021
Completion date
September 13, 2023
Enrollment
323 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of covid-19